TG Therapeutics, Inc. (TGTX)
TGTXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$63.00
+2.80 (+4.64%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $9.70bn
- P/E
- 22.6
- EPS, last 4 quarters
- $2.79
- Dividend yield
- –
- Day range
- –
- 52-week range
- $26.76 to $63.60
- Average volume
- 1.72m
- Previous close
- $60.21
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $79.67, +26.5% from here
Earnings
next estimate $0.2800Next report
Sep 2025
+912.5%
Dec 2025
-60.0%
Mar 2026
-26.1%
Jun 2026
-87.8%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $161.71m | $192.57m | $204.92m | $240.34m |
| Gross profit | $133.62m | $154.43m | $171.41m | $199.14m |
| Operating income | $29.36m | $50.49m | $34.80m | $21.67m |
| Net income | $390.89m | $23.04m | $19.78m | $7.78m |
Last four quarters: revenue $799.54m, margin 55.2%, free cash flow $17.39m
News
8 latest- TG Therapeutics (TGTX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 24 minutes ago
- TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceFintel · 10 hours ago
- TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to SayZacks · 12 hours ago
- TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue EstimatesZacks · 14 hours ago
- Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in FocusZacks · 3 days ago
- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownZacks · 3 days ago
- IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D CostsZacks · 4 days ago
- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthZacks · 4 days ago
The company
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- tgtherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.